Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programGiuseppe Procopio, Elena Verzoni, Giacomo Cartenì et al.|Journal for ImmunoTherapy of Cancer|2019Cited by 140
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.Vincenzo Gennusa, Edoardo Francini, Elisa Zanardi et al.|Journal of Clinical Oncology|2023Cited by 1
Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study.Richard M. Lee‐Ying, Edoardo Francini, Calogero Saieva et al.|Journal of Clinical Oncology|2023Cited by 0